BioAge Labs Reports First Quarter 2025 Financial Results and Provides Business Updates

Rhea-AI Summary

BioAge Labs (BIOA) reported its Q1 2025 financial results and business updates, highlighting progress in its metabolic disease therapeutics pipeline. The company's lead candidate BGE-102, an oral brain-penetrant NLRP3 inhibitor for obesity, is advancing with initial Phase 1 data expected in H2 2025. BioAge announced a strategic collaboration with Lilly ExploR&D to develop therapeutic antibodies and continues to advance its APJ agonist program for obesity.

Financial results show R&D expenses increased to $11.1 million from $9.3 million YoY, while G&A expenses rose to $6.8 million from $3.5 million. The company reported a net loss of $12.9 million ($0.36 per share). BioAge maintains a strong financial position with $335.1 million in cash and equivalents, expected to fund operations through 2029.

Positive

• Strong cash position of $335.1 million, sufficient to fund operations through 2029
• New strategic collaboration with Lilly ExploR&D for therapeutic antibodies development
• Lead candidate BGE-102 showing potential best-in-class potency in preclinical studies
• Slight improvement in net loss per share from $7.76 in Q1 2024 to $0.36 in Q1 2025

Negative

• R&D expenses increased by $1.8 million YoY to $11.1 million
• G&A expenses nearly doubled to $6.8 million from $3.5 million YoY
• Net loss of $12.9 million for Q1 2025

Insights

Biotech Financial Analyst

BioAge reports strong $335.1M cash position with runway through 2029 while advancing obesity pipeline and securing Lilly partnership.

BioAge's Q1 2025 financial results reveal a remarkably strong cash position of $335.1 million, providing runway through 2029. This extensive cash cushion—unusual for a clinical-stage biotech—gives management significant operational flexibility to advance multiple programs without near-term financing pressure.

R&D expenses increased to $11.1 million (19% year-over-year), primarily driven by IND-enabling activities for lead candidate BGE-102. G&A expenses rose more substantially to $6.8 million (94% increase), largely due to $2 million in higher personnel costs, including increased stock-based compensation.

Net loss remained essentially flat at $12.9 million versus $13 million in Q1 2024, suggesting effective cost management despite pipeline advancement. The dramatic improvement in loss per share from $7.76 to $0.36 reflects a significantly expanded share count following public market entry.

The strategic collaboration with Lilly ExploR&D targeting novel metabolic aging pathways represents an important validation of BioAge's platform approach. While financial terms weren't disclosed, such partnerships typically include upfront payments, R&D funding, and milestone opportunities that could enhance BioAge's financial profile.

With multiple value-driving catalysts expected—including BGE-102 Phase 1 data in 2H25 and a potential APJ agonist candidate nomination by year-end—BioAge has established a solid financial foundation to execute its metabolic disease strategy without immediate capital constraints.

Pharmaceutical R&D Expert

BioAge advances brain-penetrant NLRP3 inhibitor for obesity with differentiated mechanism; clinical data expected 2H25 amid expanding pipeline.

BioAge's strategic focus on the biology of aging applied to metabolic disease is materializing with several meaningful pipeline advancements. The company's lead program BGE-102, a novel brain-penetrant NLRP3 inhibitor nominated in January 2025, represents a mechanistically differentiated approach to obesity treatment.

NLRP3 inflammasome activation forms a critical link between inflammation and metabolic dysfunction. BGE-102's brain penetration capability is particularly noteworthy, as neuroinflammation increasingly appears connected to appetite regulation and metabolic control. Preclinical studies have demonstrated significant weight loss potential through NLRP3 inhibition, though specific efficacy metrics weren't disclosed.

The development timeline appears ambitious but achievable—the company is currently conducting IND-enabling studies with the goal of initial Phase 1 data in the second half of 2025. This suggests confidence in their preclinical safety package to date.

BioAge is prudently building a multi-modal metabolic disease portfolio beyond BGE-102. The APJ agonist program, targeting the apelin receptor system known to regulate metabolism and cardiovascular function, continues advancing toward candidate nomination by year-end 2025.

The new Lilly collaboration brings antibody development capabilities against two novel metabolic aging targets identified through BioAge's discovery platform. This partnership with a leading metabolic disease player substantiates their target identification approach while diversifying their therapeutic modalities.

With multiple programs advancing and first-in-human data anticipated within months, BioAge is positioning itself at the intersection of aging biology and metabolic disease with a scientifically differentiated obesity strategy.

• Advancement of lead candidate BGE-102, an oral, brain-penetrant NLRP3 inhibitor for obesity, with initial clinical data expected 2H25
  
• New strategic collaboration with Lilly ExploR&D expands therapeutic approach to novel metabolic aging targets
  
• Progression of preclinical next-generation APJ agonists for obesity
  

RICHMOND, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. ("BioAge", “the Company”), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging, today provided business updates and reported its first quarter 2025 financial results.

“The first quarter of 2025 was marked by strategic execution as we advanced our focused pipeline," said Kristen Fortney, Ph.D., CEO and co-founder of BioAge. "We've made significant progress with BGE-102, our brain-penetrant NLRP3 inhibitor, and are on track with IND-enabling studies to bring this potential best-in-class compound to the clinic this year, with initial Phase 1 data expected before year-end. Our new collaboration with Lilly expands our therapeutic capabilities into antibodies while validating our platform-driven approach to targeting the biology of aging. Meanwhile, both our novel APJ agonist program and our partnership with Novartis continue to make meaningful progress. With these scientific advancements and our strong financial position, we're well-positioned to deliver on our mission to leverage the biology of aging to develop transformative treatments for metabolic diseases."

First Quarter 2025 Business Highlights

NLRP3 program development 

• In January 2025, BioAge nominated BGE-102, a novel, orally available small-molecule NLRP3 inhibitor, as its lead development candidate for obesity. The compound shows potential best-in-class potency and brain penetration, and can target diseases driven by neuroinflammation including metabolic conditions and obesity. In preclinical studies, NLRP3 inhibition has demonstrated significant weight loss potential. IND-enabling studies are currently underway, with initial Phase 1 data anticipated in the second half of 2025.
  
  

Strategic collaborations

• In January 2025, BioAge announced a strategic collaboration with Lilly ExploR&D to develop two therapeutic antibodies targeting novel metabolic aging targets identified through BioAge's discovery platform.
  
  

Pipeline advancement

• The Company continues to advance its portfolio of novel, structurally differentiated APJ agonists for obesity and related metabolic conditions, with the goal of nominating a development candidate by the end of 2025. BioAge's multi-year research collaboration with Novartis, focused on discovering novel therapeutic targets at the intersection of aging biology and exercise physiology, continues to make meaningful progress.
  
  

First Quarter 2025 Financial Results

Research and development expenses were $11.1 million for the quarter ended March 31, 2025, compared to $9.3 million for the same period in 2024. The $1.8 million increase in research and development expenses was primarily attributable to a $2.7 million increase in direct costs related to other programs as BioAge focused its research and development activities on IND-enabling activities for BGE-102.

General and administrative expenses were $6.8 million for the quarter ended March 31, 2025,, compared to $3.5 million for the same period in 2024. The $3.3 million increase was primarily attributable to a $2.0 million increase in personnel-related expenses, which was largely attributable to increased stock-based compensation expense associated with option grants issued to employees, executives, board members and advisors. Additionally, contributing to the increase was a $0.5 million increase in legal fees, and a $0.4 million increase in taxes and insurance, primarily related to our public-company director and officer insurance policy.

Net loss was $12.9 million for the quarter ended March 31, 2025, or $0.36 per weighted-average common share outstanding, basic and diluted, compared to a net loss of $13.0 million, or $7.76 per weighted-average common share outstanding, basic and diluted, for the same period in 2024.

As of March 31, 2025, BioAge had approximately $335.1 million in cash, cash equivalents, and marketable securities. Based on our current operating plan, BioAge estimates that existing cash, cash equivalents, and marketable securities will be sufficient to fund operations and capital expenses through 2029.

About BioAge Labs, Inc.

BioAge is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. The company’s pipeline includes novel, orally available, brain-penetrant small-molecule NLRP3 inhibitors to treat metabolic diseases and conditions driven by neuroinflammation, as well as novel APJ agonists for metabolic disorders. BioAge’s additional preclinical programs, which leverage insights from the Company’s proprietary discovery platform built on human longevity data, address key pathways involved in metabolic aging.

Forward-looking statements

This press release contains “forward-looking statements” within the meaning of, and made pursuant to the safe harbor provisions of, the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding our plans to develop and commercialize our product candidates, the timing and results of our planned clinical trials, risks associated with clinical trials, including our ability to adequately manage clinical activities, the timing of and our ability to obtain and maintain regulatory approvals, the clinical utility of our product candidates, the sufficiency of our cash and cash equivalents, and general economic, industry and market conditions. These forward-looking statements may be accompanied by such words as “aim,” “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “might,” “plan,” “potential,” “possible,” “will,” “would,” and other words and terms of similar meaning. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including: our ability to develop, obtain regulatory approval for and commercialize our product candidates; the timing and results of preclinical studies and clinical trials; the risk that positive results in a preclinical study or clinical trial may not be replicated in subsequent trials or success in early stage clinical trials may not be predictive of results in later stage clinical trials; risks associated with clinical trials, including our ability to adequately manage clinical activities, unexpected concerns that may arise from additional data or analysis obtained during clinical trials, regulatory authorities may require additional information or further studies, or may fail to approve or may delay approval of our drug candidates; the occurrence of adverse safety events; failure to protect and enforce our intellectual property, and other proprietary rights; failure to successfully execute or realize the anticipated benefits of our strategic and growth initiatives; risks relating to technology failures or breaches; our dependence on collaborators and other third parties for the development of product candidates and other aspects of our business, which are outside of our full control; risks associated with current and potential delays, work stoppages, or supply chain disruptions, including due to the imposition of tariffs and other trade barriers; risks associated with current and potential future healthcare reforms; risks relating to attracting and retaining key personnel; changes in or failure to comply with legal and regulatory requirements, including shifting priorities within the U.S. Food and Drug Administration; risks relating to access to capital and credit markets; and the other risks and uncertainties that are detailed under the heading “Risk Factors” included in BioAge’s Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission (SEC) on May 6, 2025, and BioAge’s other filings with the SEC filed from time to time. BioAge undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Contacts
PR: Chris Patil, media@bioagelabs.com
IR: Dov Goldstein, ir@bioagelabs.com
Partnering: partnering@bioagelabs.com
Web: https://bioagelabs.com

BIOAGE LABS, INC. Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss (in thousands, except share and per share information)
	Three Months Ended
	March 31,
	2025				2024
Collaboration revenue	$	1,451			$	—
Operating expenses:
Research and development	$	11,109			$	9,321
General and administrative		6,788				3,492
Total operating expenses		17,897				12,813
Loss from operations		(16,446	)			(12,813	)
Other income (expense)
Interest expense		(255	)			(1,217	)
Interest and other income (expense), net		3,714				1,296
Gain (loss) from changes in fair value of warrants		59				(8	)
Loss on extinguishment of debt		—				(250	)
Total other income (expense), net		3,518				(179	)
Net loss	$	(12,928	)		$	(12,992	)
Net loss per share attributable to common stockholders, basic and diluted	$	(0.36	)		$	(7.76	)
Weighted-average common shares outstanding, basic and dilutive		35,850,037				1,673,472
Comprehensive loss:
Net loss		(12,928	)			(12,992	)
Other comprehensive income:
Unrealized holding gains on available-for-sale investments		29				—
Foreign currency translation adjustment		(10	)			21
Total other comprehensive income:		19				21
Total comprehensive loss	$	(12,909	)		$	(12,971	)

BIOAGE LABS, INC. Unaudited Condensed Consolidated Balance Sheets (in thousands, except share and per share information)
	March 31,				December 31,
	2025				2024
Assets
Current Assets:
Cash and cash equivalents	$	257,486			$	354,349
Marketable securities, current		63,032				—
Accounts receivable		361				—
Prepaid expenses and other current assets		3,934				2,754
Total current assets		324,813				357,103
Investments		100				100
Marketable securities		14,559				—
Property and equipment, net		929				591
Operating lease right-of-use assets, net		3,201				200
Other assets		239				240
Total assets	$	343,841			$	358,234
Liabilities
Current Liabilities:
Accounts payable	$	3,989			$	1,996
Accrued expenses and other current liabilities		4,866				11,751
Term loan, current		6,000				6,000
Operating lease liabilities, current		700				202
Deferred revenue, current		8,183				7,826
Total current liabilities		23,738				27,775
Deferred revenue		3,227				4,674
Term loan		1,056				2,502
Warrant liability		97				156
Operating lease liabilities		2,556				—
Total liabilities		30,674				35,107
Commitments and Contingencies (Note 8)
Stockholders’ Equity
Preferred stock, $0.00001 par value; 10,000,000 shares authorized as of March 31, 2025 and December 31, 2024; no shares issued or outstanding as of March 31, 2025 and December 31, 2024		—				—
Common stock, $0.00001 par value; 500,000,000 shares authorized as of March 31, 2025 and December 31, 2024; 35,850,037 shares issued and outstanding as of March 31, 2025 and December 31, 2024		—				—
Additional paid-in-capital		578,642				575,693
Accumulated other comprehensive income		264				245
Accumulated deficit		(265,739	)			(252,811	)
Total stockholders’ equity		313,167				323,127
Total liabilities and stockholders’ equity	$	343,841			$	358,234

FAQ

What were BioAge Labs (BIOA) key financial results for Q1 2025?

BioAge reported a net loss of $12.9 million ($0.36 per share), R&D expenses of $11.1 million, and G&A expenses of $6.8 million. The company has $335.1 million in cash and equivalents, sufficient to fund operations through 2029.

What is BioAge's (BIOA) lead drug candidate and when are clinical results expected?

BioAge's lead candidate is BGE-102, an oral brain-penetrant NLRP3 inhibitor for obesity. Initial Phase 1 clinical data is expected in the second half of 2025.

What new partnerships did BioAge (BIOA) announce in Q1 2025?

BioAge announced a strategic collaboration with Lilly ExploR&D to develop two therapeutic antibodies targeting novel metabolic aging targets identified through BioAge's discovery platform.

How long can BioAge (BIOA) fund its operations with current cash reserves?

With $335.1 million in cash, cash equivalents, and marketable securities, BioAge estimates it can fund operations and capital expenses through 2029.

What therapeutic areas is BioAge (BIOA) focusing on?

BioAge is focusing on metabolic diseases, particularly obesity, by developing therapeutics that target the biology of human aging through programs like NLRP3 inhibition and APJ agonists.